No Data
No Data
Ruikang Pharmaceutical (002589.SZ) announced first-quarter results, net profit of 15.169 million yuan, a decrease of 28.31%
Ruikang Pharmaceutical (002589.SZ) released its report for the first quarter of 2024, achieving 20 operating income during the reporting period...
Benign Growth For Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) Underpins Stock's 30% Plummet
To the annoyance of some shareholders, Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) shares are down a considerable 30% in the last month, which continues a horrid run for the company. The d
Further Weakness as Realcan Pharmaceutical Group (SZSE:002589) Drops 12% This Week, Taking Five-year Losses to 60%
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example the Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) share price dr
Ruikang Pharmaceutical (002589.SZ): 2023 pre-profit of 20 million yuan to 30 million yuan
Gelonghui, January 30 | Ruikang Pharmaceutical (002589.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 20 million yuan to 30 million yuan, turning a year-on-year loss into a profit; net profit loss after deducting non-recurring profit and loss was 130 million yuan to 190 million yuan, a decrease of 79.52%-85.98% compared to the same period last year; basic earnings per share were 0.0133 yuan/share to 1990.00.0/share. The main reason why the 2023 results turned a loss into a profit compared to the same period of the previous year: the disposal of subsidiaries affects investment income and fair value
Ruikang Pharmaceutical (002589.SZ) received a warning letter from the Shandong Securities Regulatory Bureau
Ruikang Pharmaceutical (002589.SZ) announced that the company received “On Ruikang Pharmaceutical Group Shares...” issued by the Shandong Securities Regulatory Bureau
Does Realcan Pharmaceutical Group (SZSE:002589) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
No Data